Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAH K TASIAN

Allopathic & Osteopathic Physicians Pediatrics Pediatric Hematology-Oncology

NPI
1013027077
CMS profile
1132369
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$40,847.07

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $27,489.00 3
Travel and Lodging $12,893.22 12
Food and Beverage $464.85 10

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Amgen Inc. $22,984.36 20
JAZZ PHARMACEUTICALS INC. $17,177.71 4
AstraZeneca Pharmaceuticals LP $685.00 1

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAH K TASIAN

NPI 1013027077 · CMS profile ID 1132369

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Hematology-Oncology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013027077?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013027077?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013027077?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SARAH K TASIAN, NPI 1013027077, CMS profile ID 1132369, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1013027077?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $40,847.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $143.4312/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150194987 CMS
JAZZ PHARMACEUTICALS INC. $16,500.0006/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150194981 CMS
JAZZ PHARMACEUTICALS INC. $418.2706/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150194983 CMS
Amgen Inc. $58.1105/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116171029 CMS
Amgen Inc. $10,304.0005/29/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116171036 CMS
Amgen Inc. $15.2805/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116171042 CMS
Amgen Inc. $42.0105/29/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116171050 CMS
JAZZ PHARMACEUTICALS INC. $116.0105/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150194985 CMS
Amgen Inc. $11,626.4001/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805962 CMS
Amgen Inc. $120.8901/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805964 CMS
Amgen Inc. $120.8901/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805966 CMS
Amgen Inc. $120.8901/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805968 CMS
Amgen Inc. $164.8501/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805970 CMS
Amgen Inc. $214.3101/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805972 CMS
Amgen Inc. $2.2001/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805974 CMS
Amgen Inc. $2.2001/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805976 CMS
Amgen Inc. $2.2001/26/2024 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1155805978 CMS
Amgen Inc. $32.4201/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805980 CMS
Amgen Inc. $32.4201/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805982 CMS
Amgen Inc. $49.4601/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805984 CMS
Amgen Inc. $49.4601/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805986 CMS
Amgen Inc. $8.7901/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805988 CMS
Amgen Inc. $8.7901/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805990 CMS
Amgen Inc. $8.7901/26/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155805992 CMS
AstraZeneca Pharmaceuticals LP $685.0001/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105215655 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125.18 1
PY2022 $12,692.29 5
PY2023 $16,204.01 8
PY2024 $40,847.07 25
PY2025 $19,866.78 23

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $376,661.72 26
PY2024 Principal investigator $492,636.09 23
PY2023 Principal investigator $24,589.12 11
PY2022 Principal investigator $39,173.75 6
PY2021 Principal investigator $433.67 12
PY2020 Principal investigator $178.59 4
PY2019 Recipient $93.48 2
PY2019 Principal investigator $326.23 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

11 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $15,260.00 12/07/2023 Non-covered Recipient Entity
CHILDREN'S HOSPITAL OF PHILADELPHIA
B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy No dispute reported 06/30/2026 998410817
Principal investigator 1 Astellas Pharma Global Development $2,593.75 12/06/2023 Non-covered Recipient Entity
The Childrens Hospital Of Philadelphia
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1138725096
Principal investigator 1 Astellas Pharma Global Development $2,126.25 10/11/2023 Non-covered Recipient Entity
THE CHILDRENS HOSPITAL OF PHILADELPHIA
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1138725098
Principal investigator 1 Astellas Pharma Global Development $1,540.00 08/03/2023 Non-covered Recipient Entity
THE CHILDRENS HOSPITAL OF PHILADELPHIA
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1138725100
Principal investigator 1 Astellas Pharma Global Development $1,215.00 03/09/2023 Non-covered Recipient Entity
THE CHILDRENS HOSPITAL OF PHILADELPHIA
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1022261113
Principal investigator 1 Astellas Pharma Global Development $1,755.00 02/15/2023 Non-covered Recipient Entity
THE CHILDRENS HOSPITAL OF PHILADELPHIA
A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) No dispute reported 06/30/2026 1022261103
Principal investigator 1 Incyte Corporation $40.86 01/10/2023 Non-covered Recipient Entity
OREGON DERMATOLOGY AND RESEARCH CENTER
A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1040911153
Principal investigator 1 Incyte Corporation $12.36 01/10/2023 Non-covered Recipient Entity
OREGON DERMATOLOGY AND RESEARCH CENTER
A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1040911165
Principal investigator 1 Incyte Corporation $21.18 01/10/2023 Non-covered Recipient Entity
OREGON DERMATOLOGY AND RESEARCH CENTER
A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1040911179
Principal investigator 1 Incyte Corporation $12.36 01/10/2023 Non-covered Recipient Entity
OREGON DERMATOLOGY AND RESEARCH CENTER
A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1040911195
Principal investigator 1 Incyte Corporation $12.36 01/10/2023 Non-covered Recipient Entity
OREGON DERMATOLOGY AND RESEARCH CENTER
A Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearranged and or JAK Pathway Mutant Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1040911205